Therapy with anti-PD-L1 immune check-point inhibitors is approved for several cancers, including advanced urothelial carcinomas. PD-L1 prevalence estimates vary widely in bladder cancer, and lack of correlation between expression and clinical outcomes and immunotherapy response may be attributed to methodological differences of the immunohistochemical reagents and procedures. We characterized PD-L1 expression in 235 urothelial carcinomas including 79 matched pairs of primary and metastatic cancers using a panel of four PD-L1 immunoassays in comparison with RNAscope assay using PD-L1-specific probe (CD274). The antibody panel included three FDA-approved clones (22C3 for pembrolizumab, 28.8 for nivolumab, SP142 for atezolizumab), and a commonly used clone E1L3N. Manual scoring of tissue microarrays was performed in each of 235 tumors (624 tissue cores) and compared to an automated image analysis. Expression of PD-L1 in tumor cells by ≥ 1 marker was detected in 41/142 (28.9%) primary tumors, 13/77 (16.9%) lymph nodes, and 2/16 (12.5%) distant metastases. In positive cases, high PD-L1 expression (450% cells) was detected in 34.1% primary and 46.7% metastases. Concordant PD-L1 expression status was present in 71/79 (89.9%) cases of matched primary and metastatic urothelial carcinomas. PD-L1 sensitivity ranked from highest to lowest as follows: RNAscope, clone 28.8, 22C3, E1L3N, and SP142. Pairwise concordance correlation coefficients between the four antibodies in 624 tissue cores ranged from 0.76 to 0.9 for tumor cells and from 0.30 to 0.85 for immune cells. RNA and protein expression levels showed moderate to high agreement (0.72-0.87). Intra-tumor expression heterogeneity was low for both protein and RNA assays (interclass correlation coefficients: 0.86-0.94). Manual scores were highly concordant with automated Aperio scores (0.94-0.97). A significant subset of 56/235 (23.8%) urothelial carcinomas stained positive for PD-L1 with high concordance between all four antibodies and RNA ISH assay. Despite some heterogeneity in staining, the overall results are highly concordant suggesting diagnostic equivalence of tested assays.
A highly promising and rapidly emerging approach to cancer immunotherapy is antibody-mediated blockade of inhibitory co-receptors expressed on T-lymphocytes, or so-called immune checkpoints. Programmed cell death-1 (PD-1; CD279) is one of immune check-point receptors of T-cells and its interaction with the PD-1 receptor-ligand (PD-L1; CD274) is a major pathway hijacked by tumors to suppress immune control. [1] [2] [3] The PD-L1trans-membrane protein is normally expressed at very low levels in peripheral tissues with a few exceptions like placental trophoblast, tonsil, and hematopoietic cells where increased PD-1/PD-L1 signaling dampens unwarranted T-cell function and autoimmunity. [4] [5] [6] However, a variety of cancers show increased membranous expression of these T-cell inhibitors, thus binding of either PD-1 or PD-L1 unmasks tumor cells leading to their lysis by activated T-cells.
Immunotherapy aimed at inhibiting PD-1/PD-L1 has been recently approved and successfully utilized for several cancers including bladder cancer. 3, [7] [8] [9] [10] Yet, factors associated with benefit from such therapy remain under investigation. As PD-1/PD-L1 tissue expression could be established by immunohistochemistry, it is logical to assume their role as predictive biomarkers allowing patient selection for enriched therapy benefit. 2, 11 Recently several anti-PD-L1 assays were developed and approved as companion and/or complementary immunohistochemical assays for specific drugs and tumor types using different antibodies, staining platforms, scoring guidelines, and definitions of PD-L1 positivity ranging from any expression to 50%. 8, 12 PD-L1 expression testing is highly regulated and limited with FDA approval requiring particular application, assay, testing platform, and specific scoring recommendations tailored to different antibody clone, tissue types, and associated drug. 1, 13 This poses a logistical problem for the diagnostic laboratories in offering PD-L1 testing, its interpretation, and predicting treatment response. 6, 14 Moreover, it raises a question of different assays compatibility, sensitivity and specificity given a common target and similar mechanism of action for anti-PD-1/PD-L1 drugs.
We aimed to establish prevalence, extent, and concordance of PD-L1 expression in a large cohort of primary and metastatic bladder cancer based on four most commonly used antibodies including a platformindependent clone E1L3N, and 3 FDA-approved clones: 22C3 (Keytruda), 28.8 (Opdivo), and SP142 (Tecentriq). We also evaluated methodological accuracy of protein detection by comparison with RNAscope assay using manual and automated scoring.
Materials and methods

Case Selection and Tissue Microarrays
This study was conducted with approvals from the University of Washington and The University of Chicago institutional review boards and included 235 tumors from 156 patients obtained from pathology archives from 2004 thought 2012. High-density tissue microarrays were constructed using 63 primary urothelial carcinomas, 74 urothelial carcinomas with matched primary tumor and regional lymph node metastases, and additional 16 distant metastases with 5 matching primary urothelial carcinomas. Each tumor was represented by two to six 1 mm cores (total of 624 cores, mean = 4 cores per patient): 1-3 cores from the primary tumor and 1-6 cores from metastases. The 101 patients with available demographic data were 65% male, with age ranging from 25 to 89 years (mean = 67.9). Tumor size ranged from 1 to 10 cm (mean = 4.3 cm) with the following histology: pure urothelial (n = 136) and mixed urothelial with variant morphologies (n = 20) including micropapillary (n = 11), squamous differentiation (n = 2), glandular (n = 1), squamous and glandular (n = 1), plasmacytoid (n = 1), signet ring (n = 1), and adenocarcinoma (n = 3).
Immunohistochemistry and Manual Scoring
All immunostains were performed at PhenoPath reference laboratory (CLIA certified, CAP certified). Tissue microarray slides were stained with 4 anti-PD-L1 monoclonal antibodies using same protocols as for clinical cases and strictly following applicable manufacturer/FDA guidelines in retrieval, automated platforms, detection systems, controls, and interpretation (Supplementary Table 1 Figure 1) . All tissue microarrays were also stained with histiocytic marker CD163 to assure interpretation of membranous staining specific to tumor cells. Tissue microarray slides were independently manually scored by two pathologists with 410 years of expertise in genitourinary pathology, immunohistochemistry, and molecular pathology (MT, RF). Discordant cases (~10%) with minor disagreement due to borderline expression levels or abundant inflammatory cells were reviewed and consensus was achieved on all cases. For comparison purposes all four antibodies were scored for % membranous positivity of viable tumor cells and staining intensity (low and high). Multiplication of % positivity and average staining intensity yielded a modified H-score on a scale of 0-200 (0 = negative, 1-49 = low positive, 50-200 = high positive). In addition, expression of SP142 was analyzed in tumor-infiltrating immune cells for percent positivity (SP142-IC score) as per manufacturer recommendations and compared to manually scored tumor-infiltrating immune cells by three other markers.
Automated Scoring
Automated image analysis was performed on Aperio platform using a modified HER2 membranous staining algorithm. All tissue microarray slides were scanned on Aperio AT2 Scanner (Leica Biosystems/Aperio, Buffalo Grove, IL, USA), which automatically creates the high-resolution digital files. Images were then opened in web-based Spectrum Plus digital slide manager and segmented to multiple layers of tumor containing areas within each individual tissue core. The settings of membrane scoring algorithm (color thresholds, cell size, roundness, completeness, elongation, etc) were tuned to allow identification of all PD-L1 stained tumor cells.
Region of interest within each tissue microarray spot contained representative tumor with at least 100 cells (Supplementary Figure 2) . The most important data output parameters included total number of analyzed tumor cells (mean = 211 per core), number of positive tumor cells, average membrane staining intensity, and calculated composite score on a scale of 0-200 for comparison with manual scores.
In Situ RNA Detection and Scoring RNAscope manual procedure was performed at PhenoPath laboratories following standard protocol as previously described with minor modifications. 15 In brief, tissue microarray slides were baked in dry oven for 1 h, soaked in xylene twice for 5 min each, incubated for 1 min in 100% ethanol twice and air dried. Pre-treatment of slides was done by boiling for 15 min in RNAscope target retrieval buffer solution and protease digestion in HybEx oven at 40°C for 30 min with multiple washes. PD-L1-specific probe (CD274) obtained from Advanced Cell Diagnostics (Newark, CA; cat#600861) was applied for 2 h at 40°C in HybEx oven. After washes this step was followed by signal amplification steps, signal detection using FAST RED RNAscope 2.5 HD Detection reagent, hematoxylin counterstaining, slide clearing, and coverslip mounting.
Scoring of the RNAscope PD-L1 assay signals was performed manually by two pathologists (MT, RF) with consensus achieved in all cores. The numbers of signals (dots) were assessed on tumor cells only and interpreted according to manufacturer recommendations (Advanced Cell Diagnostics). The RNAscope scoring was done as follows: 0 if no staining or o 1 dot/10 tumor cells; 1 in 1-3 dots/cell, 2 in 4-9 dots/cell, 3 in 10-15 dots/cell, and 4 in 415 dots/ cell (Supplementary Figure 1) . A composite RNAscope score was calculated similarly to immunohistochemical H-score as a percentage of positive tumor cells multiplied by average staining score.
Statistical Analysis
Descriptive statistics were used to summarize expression by core. Each core was classified as positive (40 expression) or negative (0 expression). Tumors with multiple cores were classified as positive if any cores were positive. Patients with multiple tumors were classified as positive if any of the patient's cores were positive. Continuous variables were compared between groups using a twosample t-test, and categorical variables were compared using the χ 2 test. Overall survival was defined as time from diagnosis to death from any cause. Overall survival was estimated using the method of Kaplan-Meier, and compared between groups using the log-rank test. Hazard ratios were estimated using the Cox proportional hazards model. Agreement between assay expression in all cores was assessed using Lin's concordance correlation coefficient 16 and calculated R package epiR. 17, 18 Intraclass correlation coefficient was used to summarize the inter-assay reliability among multiple cores per patient or per tumor, and was estimated using intraclass correlation coefficient package in R. 19 
Results
We analyzed 624 cores from 235 distinct tumors (primary, lymph node or distant metastases) that came from 156 patients. PD-L1 expression was positive by ≥ 1 marker in 56/235 (23 Figure 1 ).
Association of PD-L1 Expression, Clinico-Pathological Features, and Overall Survival
Demographic information, tumor characteristics, and follow-up data were available for 101 of 156 patients. None of the patients were treated with anti-PD-1 or anti-PD-L1 check-point inhibitors. Clinicopathological features were not found to be significantly associated with PD-L1 positivity in tumor cells by ≥ 1 marker or in immune cells with SP142-IC (Table 1 ). There were 16 deaths, with median followup of 11 months (range 2-127). PD-L1 staining in tumor cells by ≥ 1 was associated with improved survival (HR = 0.26 (95% CI: 0.14-1.13); P = 0.0585, log-rank test) (Figure 2) , with nearly identical estimates for positive staining with ≥ 2 markers (HR = 0.39 (95% CI: 0.14-1.15); P = 064, log-rank test). PD-L1 staining in immune cells (SP142-IC) was associated with overall survival (HR = 0.25 (95% CI: 0.06-1.11); P = 0.0463, log-rank test).
Comparison of Four Immunohistochemical and RNA ISH Assays for Sensitivity
Frequency of PD-L1 expression in tumor cells (% positivity) was similar across assays, with the highest rates for clone 28.8 (18.6%) and RNA ISH (20.5%) (Supplementary Table 2 ). Among the 132 cores with ≥ 1 positive marker, staining intensity multiplied by % positivity (H-score) as a measure of assay sensitivity was (ranked from highest to lowest) as follows: RNA ISH (64.6 ± 60), 28.8 (54.8 ± 66), 22C3 (43.5 ± 63), E1L3N (37.1 ± 55.7) and SP142 (32.6 ± 57.1). H-scores for immunoassays were higher in distant metastases (range: 123.3-160) than in primary tumors (range: 33.1-53.1), and were lowest in lymph node metastases (range: 12.8-38.9).
Concordance of Four Chromogenic Immunohistochemical Assays
Pairwise comparison of tumor cell staining by four antibodies showed high agreement between markers (Table 2a) . Concordance correlation coefficients ranged from 0.76 to 0.90 for all cores, and from 0.69 to 0.86 for cores positive by ≥ 1 marker. The highest agreement was reached between 22C3/28.8 and 28.8/E1L3N pairs, whereas the lowest agreement was seen between 22C3/SP142 and 28.8/SP142, (18) 2 (7) 14 (20) a Non-UC cases included tumors with variant morphology such as micropapillary (n = 11), squamous differentiation (n = 2), glandular (n = 1), squamous and glandular (n = 1), plasmacytoid (n = 1), signet ring (n = 1), and adenocarcinoma (n = 3). (Table 2b) .
Correlation Between Protein Expression Levels and RNA ISH in Tumor Cells
The RNA ISH and protein expression levels in all 624 cores showed moderate to high correlation with concordance correlation coefficients ranging from 0.72 to 0.87 (Table 3 
Correlation Between PD-L1 Protein Expression Levels in Tumor Cells vs Immune Cells
Frequency of PD-L1 expression in immune cells (% positivity) assessed on SP142 immunostaining (SP142-IC) was 22.8% in primary urothelial carcinomas, 17.4% in lymph node mets and 27.1% in distant mets (Supplementary Table 2 Table 3 ). The highest pairwise agreement was between SP142-IC and SP142-tumor, whereas the lowest agreement was between SP142-IC and clones 22C3 and 28.8. Correlation was the lowest in lymph node metastases and distant metastases (range: 0.1-0.41).
Intra-Tumor Heterogeneity of PD-L1 Protein and mRNA Expression
The intra-tumor heterogeneity was assessed by comparing expression levels across tissue cores derived from the same tumor (Supplementary Table 4 ). The intraclass correlation coefficients for overall intra-tumor heterogeneity showed excellent concordance for all 4 PD-L1 clones in tumor cells (range: 0.90-0.94). PD-L1 intra-tumor heterogeneity was lowest in primary tumors (range: 0.95-0.98), and slightly higher in lymph nodes (range: 0.76-0.98) and distant metastases (range: 0.75-1). RNAscope results were highly concordant for both primary and metastatic sites (range: 0.87-0.98).
PD-L1 expression on tumor-infiltrating immune cells showed low heterogeneity for all four clones in primary tumors (range: 0.89-0.93) and lymph node metastases (range: 0.83-0.94), and slightly higher heterogeneity in distant metastases (range: 0.6-0.73).
Manual Scoring vs Automated Image Analysis Agreement
Comparison of manual scores and Aperio-generated combined scores showed excellent concordance for all tissue microarray cores (negative and positive) with concordance correlation coefficients ranging between 94 and 96% agreement, and concordance correlation coefficients ranging between 92 and 96% among positive cores (Supplementary Table 5 ). However, concordance correlation coefficients in positive distant metastases was lower for clones 28.8 (concordance correlation coefficient: 0.62) and clone SP142 (concordance correlation coefficient: 0.79). This could be attributed to higher background staining for 28.8, and punctate staining pattern instead of continuous membranous pattern for clone 
Discussion
PD-L1 immunohistochemical testing in cancer tissues suffer from lack of standardization and from limited validation, resulting in wide variety of assays that use different antibodies, reagents, staining platforms, and scoring methodologies. 1, 13 Rapidly developing immunotherapy requires large-scale quantitative validation studies comparing most commonly used PD-L1 immunoassays for concordance and accurate, reproducible measurement of targeted molecule. Our study is the first to address PD-L1 assay performance in large numbers of primary and metastatic bladder cancers, which will be increasingly tested and treated by check-point inhibitors following recent accelerated FDA approvals. 8 In the present high-throughput study, we investigated the four most commonly used anti-PD-L1 antibodies (3 FDA-approved). The prevalence of PD-L1 expression by ≥ 1 marker in all bladder cancers (N = 235) was 23.8%, with slightly higher prevalence in primary urothelial carcinomas vs regional lymph node or distant metastases. Positive staining with ≥ 2 antibodies occurred in 21.1% primary, 15.6% regional metastases, and 12.5% distant metastases, nearly as often as with at least one antibody. The proportion of strongly positive cases was lower in primary tumors (34.1%) than in metastatic sites (46.7%). Importantly, we found high concordance between PD-L1 expression in matched primary and metastatic urothelial carcinomas with agreement in 89.9% cases, although the majority of our matched cases were obtained from patients with regional metastases excised at the time of primary tumor resection. Our findings in primary urothelial carcinomas are consistent with previously reported prevalence rates of PD-L1 expression in tumor cells ranging from 14 to 28%. 4, [20] [21] [22] [23] To our knowledge we are the first to report prevalence of PD-L1 expression in regional and distant urothelial carcinoma metastases.
We found high concordance between the four immunoassays in tumor cells despite the differences in antibody design, molecular properties, antigen retrievals, detection systems, and staining platforms. Similar finding of minimal inter-assay variability were reported in lung cancer for PD-L expression using various combinations of clones 22C3, 28.8, SP142, E1L3N, 9A11, and SP263. 14, 15, 24 E1L3N rabbit monoclonal antibody is the only one out of four studied here antibodies that is not FDAapproved, platform-dependent or linked to a specific pharmacological agent, although it is one of the most frequently used research antibodies. 4 Our comprehensive concordance study supported by several other reports provide strong evidence that E1L3N clone is as accurate and reproducible in detecting PD-L1 protein in urothelial carcinomas as any other FDA-approved immunoassay. 5, 15, [24] [25] [26] To avoid subjectivity in scoring, we scored all immunostains following same approach resulting in highly concordant results between manual scores and automated scores for all four immunomarkers (concordance correlation coefficients: 0.92-0.97). A recent study comparing four scoring methods showed that percentage of tumor cell staining at any intensity has similar prognostic value as more complex scoring methods, and incorporation of immune cell staining did not improve predictive value of PD-L1 (clone 22C3) in lung cancer. 27 We found that patients with PD-L1 positive tumors by ≥ 1 marker and with PD-L1 negative tumors were similar in age, sex, histopathological, and clinical parameters. However, presence of any PD-L1 expression in tumor cells was associated with improved overall survival (P = 0.058). PD-L1 expression in tumor-infiltrating immune cells was present in 27 tumors and also was associated with improved outcomes (P = 0.046). The overall impact of PD-L1 expression on prognosis remains controversial likely due to variability of methodologies for evaluating PD-L1 expression and its scoring. 6, [20] [21] [22] [23] Taube et al 28 found that PD-L1 staining of tumor cells in various tumors was more predictive of response to anti-PD-1 check-point blockade than PD-L1 expression on immune cells. However, for bladder cancer it remains unclear whether PD-L1 expression in tumor cells or in immune cells is more predictive of outcome and treatment response. 1, 3, 7, 11, 21, 26 On May 2016, FDA granted accelerated approval for atezolizumab (Tecentriq) to treat patients with locally advanced or metastatic urothelial carcinomas after platinum-containing chemotherapy. 8 The objective response rates were increased in patients with 45% immune cells by SP142 assay; however, this agreement was modest and some complete responders were reported with negative SP142-IC staining. Similar to atezolizumab antitumor activity has been reported for other PD-1 or PD-L1-targeted products (eg, avelumab, durvalumab, pembrolizumab, and nivolumab) in advanced urothelial carcinoma. 8, 9, 26, 29 Not surprisingly, on May 2017, FDA granted two accelerated approvals for pembrolizumab (Keytruda) and durvalumab (Imfinzi) to treat unresectable and metastatic solid tumors that have progressed following prior treatment (https:// www.fda.gov). The objective response rates in populations of 30-300 study patients were 15-52% (mean 30%) including some durable responses with good tolerance and suggesting a class effect of PD-1/ PD-L1-targeted products in the disease. 3, 10, 26 It is important to emphasize that our study showed lower sensitivity and higher intra-tumor heterogeneity of SP142 immunoassay compared to other clones in both tumor cells and immune cells, as well as only modest agreement between PD-L1 expression SP142-IC vs tumor cell expression by all four markers (concordance correlation coefficients: 0.55-0.73). The same observation was made in 'Blueprint PD-L1 immunohistochemical assay comparison project'. 14 From a pathologist perspective, separate interpretation of tumor cell and immune cell expression for clone SP142 is cumbersome and poses significant challenge in some cases. Moreover, unusual punctate, dot-like, or clump-like expression pattern instead of membranous pattern seen with other clones could prevent from reproducible interpretation of SP142 staining results. 30 Further studies addressing intriguing differences in assay sensitivity, expression heterogeneity and post-analytical variables unique to clone SP142 are warranted. Our findings also suggest that PD-L1 immunoassays other than SP142 could be utilized and should be tested for predicting durable objective response rates in patients with advanced bladder cancer.
Our study has several limitations including its retrospective nature and utilization of tissue microarrays without whole-section analysis. Recent study of conventional tissue sections revealed substantial heterogeneity of PD-L1 expression in lung cancer and resulted in higher variation of immunohistochemical results. 31 On the other hand, in clinical practice, PD-L1 assessment is frequently done on small archival tissue samples introducing preanalytical variables and sampling error similar to tissue microarray cores. Although we found that PD-L1 positivity is associated with overall survival and may serve as a prognostic marker, no conclusion could be made regarding specific treatment response as the majority of our patients had locally advanced disease with only few distant metastases, and none were treated with PD-1 axis inhibitors.
PD-L1 mRNA expression was used as a molecular correlate for PD-L1 immunoassays; however, it remains unclear whether mRNA expression could be viewed as a gold standard for PD-L1 overexpression. 13, 15 We postulated that RNA expression values, as measured by RNA ISH (RNAscope), could potentially serve as a relevant inter-method comparator. To our knowledge, RNA ISH has not been clinically or analytically validated in this context, and a variety of factors, including posttranslational protein modification, could yield discordant results between RNA and protein expression levels. Therefore, it would be premature to suggest that RNA ISH represents a gold standard test for PD-L1 assays. However, we believe the comparison of RNA and protein expression is of potential value in normalizing the results of immunohistochemical assays, generally, although further study is required to establish the performance characteristics of RNA ISH for PD-L1. In light of these considerations, it is of interest that our results indicate rather robust concordance between the two methods.
Similar performance of four immunohistochemical assays as documented by our study could potentially eliminate several issues-related PD-L1 laboratory testing when neither an ordering clinician nor pathologist can make an informed decision about test of choice. It could also potentially reduce the cost of PD-L1 testing for the patient; prevent laboratories from running multiple antibody panels and from running expensive tests where payers may not be compensated. However, slightly higher prevalence of PD-L1 expression by any one antibody vs ≥ 2 antibodies may justify a utilization of antibody panels in cases with borderline low-expression levels at the detection limit of immunoassay.
In summary, PD-L1 is expressed in a substantial proportion of primary and metastatic urothelial carcinomas in both tumor cell membranes and tumor-infiltrating immune cells. Standardized manual scoring allowed comparison of four most commonly used antibodies and RNA ISH assay showing concordant results between different antibody clones, protein and RNA expression levels, and near equivalence of manual and automated scoring.
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